Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.

Cancer Chemother Pharmacol · 2021 · PMC8536600 · PMID 34505930

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Still, we could show a highly significant correlation between vertigo and cephalgia CTCAE grade 1 and Ruxolitinib exposure.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.